Neurones Total Liabilities
Neurones total liabilities. Based on the latest financial reports, Neurones (NRO) has total liabilities worth €284.16 Million EUR (≈ $332.22 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Neurones (NRO) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Neurones (2000–2025)
Total liabilities of Neurones from 2000 to 2025. This chart illustrates how Neurones's total liabilities have evolved over time, based on quarterly financial data. Explore Neurones long-term investment intensity to see how much of total assets are deployed in long-term investments.
Neurones Competitors by Total Liabilities
The table below lists competitors of Neurones ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bioventus Inc
NASDAQ:BVS
|
USA | $395.93 Million |
|
Bata India Limited
NSE:BATAINDIA
|
India | Rs21.83 Billion |
|
Standard Lithium Ltd
NYSE MKT:SLI
|
USA | $33.74 Million |
|
Japfa Comfeed Indonesia Tbk
JK:JPFA
|
Indonesia | Rp23.81 Trillion |
|
Jade Biosciences, Inc.
NASDAQ:JBIO
|
USA | $32.20 Million |
|
Generation Development Group Ltd
AU:GDG
|
Australia | AU$5.58 Billion |
|
CureVac NV
F:5CV
|
Germany | €267.39 Million |
|
Suzhou Huaya Intelligence Technology Co Ltd
SHE:003043
|
China | CN¥1.02 Billion |
Liability Composition Analysis (2000–2025)
This chart breaks down Neurones's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Neurones balance sheet assets.
Liquidity & Leverage Metrics
Neurones Total Liabilities Ratios Explained
Neurones total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.43 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.71 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Neurones's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Neurones (2000–2025)
The table below shows the annual total liabilities of Neurones from 2000 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €284.16 Million ≈ $332.22 Million |
-1.85% |
| 2024-12-31 | €289.52 Million ≈ $338.48 Million |
+8.70% |
| 2023-12-31 | €266.34 Million ≈ $311.38 Million |
+10.68% |
| 2022-12-31 | €240.63 Million ≈ $281.33 Million |
+11.97% |
| 2021-12-31 | €214.90 Million ≈ $251.25 Million |
+12.62% |
| 2020-12-31 | €190.83 Million ≈ $223.10 Million |
+4.38% |
| 2019-12-31 | €182.82 Million ≈ $213.73 Million |
+19.35% |
| 2018-12-31 | €153.18 Million ≈ $179.08 Million |
+6.64% |
| 2017-12-31 | €143.64 Million ≈ $167.93 Million |
-2.40% |
| 2016-12-31 | €147.18 Million ≈ $172.06 Million |
+8.66% |
| 2015-12-31 | €135.45 Million ≈ $158.35 Million |
+26.24% |
| 2014-12-31 | €107.29 Million ≈ $125.44 Million |
+3.66% |
| 2013-12-31 | €103.51 Million ≈ $121.01 Million |
+9.44% |
| 2012-12-31 | €94.58 Million ≈ $110.57 Million |
+9.54% |
| 2011-12-31 | €86.34 Million ≈ $100.94 Million |
+25.79% |
| 2010-12-31 | €68.64 Million ≈ $80.24 Million |
+12.94% |
| 2009-12-31 | €60.77 Million ≈ $71.05 Million |
-11.57% |
| 2008-12-31 | €68.72 Million ≈ $80.35 Million |
+38.59% |
| 2007-12-31 | €49.59 Million ≈ $57.97 Million |
+18.79% |
| 2006-12-31 | €41.74 Million ≈ $48.80 Million |
+38.25% |
| 2005-12-31 | €30.20 Million ≈ $35.30 Million |
+6.44% |
| 2004-12-31 | €28.37 Million ≈ $33.16 Million |
+21.65% |
| 2003-12-31 | €23.32 Million ≈ $27.26 Million |
-5.82% |
| 2002-12-31 | €24.76 Million ≈ $28.94 Million |
-6.66% |
| 2001-12-31 | €26.52 Million ≈ $31.01 Million |
+34.36% |
| 2000-12-31 | €19.74 Million ≈ $23.08 Million |
-- |
About Neurones
Neurones S.A. provides infrastructure, application, and consulting services in France. The company offers cloud, infrastructure management, DevOps, cybersecurity, user support, IT service management, information system governance, and automation services. It also provides digital, UX/UI, agile, devOps, mobility, and data; SAP integration and outsourcing content management, business process manage… Read more